Sartorius Stedim Biotech SA (DIM) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

55.18 k

Shareholding (Mar 2024)

FII

0.00%

Held by 4 FIIs

DII

100.0%

Held by 0 DIIs

Promoter

0.00%

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

With ROE of 6.88%, it has a Very Expensive valuation with a 4.69 Price to Book Value

The stock is trading at a discount compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of 5.39%, its profits have risen by 45% ; the PEG ratio of the company is 1.5

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

EUR 20,186 Million ()

P/E

68.00

Industry P/E

Dividend Yield

0.96%

Debt Equity

1.39

Return on Equity

7.77%

Price to Book

5.00

Revenue and Profits:

Net Sales:

745 Million

(Quarterly Results - Jun 2025)

Net Profit:

69 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

20.95%

6 Months

1.08%

1 Year

5.39%

2 Years

-1.82%

3 Years

-35.53%

4 Years

-57.03%

5 Years

-30.63%

Sartorius Stedim Biotech SA for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

11.07%

EBIT Growth (5y)

2.90%

EBIT to Interest (avg)

7.14

Debt to EBITDA (avg)

1.85

Net Debt to Equity (avg)

0.52

Sales to Capital Employed (avg)

1.02

Tax Ratio

19.67%

Dividend Payout Ratio

38.14%

Pledged Shares

Institutional Holding

0.00%

ROCE (avg)

24.27%

ROE (avg)

21.32%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

4.69

EV to EBIT

43.21

EV to EBITDA

26.26

EV to Capital Employed

3.41

EV to Sales

7.22

PEG Ratio

1.52

Dividend Yield

1.03%

ROCE (Latest)

7.90%

ROE (Latest)

6.88%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bullish

Dow Theory

Mildly Bullish

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2024

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 4 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.05% vs -0.89% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -19.67% vs 84.45% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "745.00",
          "val2": "744.60",
          "chgp": "0.05%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "223.50",
          "val2": "228.00",
          "chgp": "-1.97%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "30.90",
          "val2": "63.30",
          "chgp": "-51.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "68.60",
          "val2": "85.40",
          "chgp": "-19.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "195.40%",
          "val2": "202.30%",
          "chgp": "-0.69%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.16% vs -20.53% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -42.92% vs -64.46% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,780.00",
          "val2": "2,775.50",
          "chgp": "0.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "721.50",
          "val2": "724.60",
          "chgp": "-0.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "158.90",
          "val2": "121.10",
          "chgp": "31.21%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-41.80",
          "val2": "57.70",
          "chgp": "-172.44%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "178.50",
          "val2": "312.70",
          "chgp": "-42.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "151.00%",
          "val2": "175.80%",
          "chgp": "-2.48%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

745.00

744.60

0.05%

Operating Profit (PBDIT) excl Other Income

223.50

228.00

-1.97%

Interest

30.90

63.30

-51.18%

Exceptional Items

0.00

Consolidate Net Profit

68.60

85.40

-19.67%

Operating Profit Margin (Excl OI)

195.40%

202.30%

-0.69%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.05% vs -0.89% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -19.67% vs 84.45% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

2,780.00

2,775.50

0.16%

Operating Profit (PBDIT) excl Other Income

721.50

724.60

-0.43%

Interest

158.90

121.10

31.21%

Exceptional Items

-41.80

57.70

-172.44%

Consolidate Net Profit

178.50

312.70

-42.92%

Operating Profit Margin (Excl OI)

151.00%

175.80%

-2.48%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.16% vs -20.53% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -42.92% vs -64.46% in Dec 2023

All Annual Results

Company CV

About Sartorius Stedim Biotech SA

Sartorius Stedim Biotech SA

Pharmaceuticals & Biotechnology

Sartorius Stedim Biotech SA is a France-based international provider of laboratory and process technologies and equipment. The Company covers the segments of biotechnology and mechatronics. Sartorius provides services which help customers to implement complex and quality-critical processes in biopharmaceutical production and laboratory environments in a time- and cost-efficient way. The Company’s customers are from the biotech, pharma and food industries, as well as from public research institutes and laboratories. Sartorius operates its own production facilities in Europe, Asia and America, and also has sales offices and local representatives in more than 110 countries. The Company operates through its subsidiaries, including Sartorius Stedim Austria GmbH, Sartorius Stedim Plastics GmbH, BioOutsource Ltd and Wave Biotech AG, among others.

Company Coordinates

Company Details

Avenue de Jouques, Zone Industrielle les Paluds, C.S. 9105, Aubagne Cedex, AUBAGNE None : 13781

Tel: 33 4 4284560049 0551 3081686

https://www.sartorius.com/en/company/about-sartorius-stedim-biotech-sa

Registrar Details